How to treat advanced kidney cancer? Which is better for kidney cancer targeting drugs?

Referring to kidney cancer, many people feel strange, compared to lung cancer, stomach cancer, liver cancer and other cancers often seen in the news, kidney cancer appears in people's vision of the frequency is very low, the domestic publicity materials on kidney cancer is relatively smallHowever, there are no fewer patients with kidney cancer in the country50,000 new kidney cancer cases are diagnosed in China each year, and the incidence of kidney cancer in China has been growing, the fastest in the world, due to factors such as smoking, overweight, family history and food contamination, like many cancers, the treatment of early kidney cancer is better, generally using surgical treatment, the cure is almost largeBut most of China's kidney cancer was found to be in the middle and late stages, of which 40% have entered the advanced stage, there has been metastasis, can not be used surgical treatment, the treatment effect of chemotherapy is also not idealLong before the advent of new targeted and immunotropic drugs, the standard treatment for advanced kidney cancer was cytokine therapy, including interferon-alpha and leukolysine-2But cytokine therapy is very flawed, only effective in a small number of patients with kidney cancer, and the side effects are very largein recent years, new targeted drug therapy has replaced cytokine therapy as the main method of treatment for advanced kidney cancer, which has improved the patient's survival and quality of life significantlykidney cancer target drugs that have been approved for listing in China are perephani, schonidine, Solafini, Ivemotis, axidine and so onThree drugs, perezoli, schoni, and Sorafenib, were approved for first-line therapy, i.ethe preferred drugSo how to choose these three target drugs, which is the best effect?the anticancer mechanism skewed by the three renal cancer targetdrugs, perephapani, scouritinib and Sorafeni, all of which are starved to death by inhibiting the formation of new blood vessels in tumorsBut the effects of the three targeted drugs are differentSorafini is the first kidney cancer target drug approved in China, but the efficacy is not very good, and the side effects are very obvious, the current international guidelines have not been so sorofani as a first-line drugthe effectiveness of theshunitinib was significantly improved by the pesolafini International Phase 3 clinical trials showed that the median progression survival of sconetinib was 11 months, compared with 5 months for interferon At present, schonitinib is the first-line treatment of advanced kidney cancer recommended by domestic and foreign guidelines But the side effects of sconetinib are still relatively large, especially in Asian patients, where the proportion of side effects such as platelet reduction is high, and many patients need to take down or discontinue their medication is the latest drug in the three and was approved for sale in China in February 2017 the efficacy of perezoli is similar to that of sconetinib, but the side effects are smaller, with fewer side effects such as fatigue, hand and foot syndrome, and reduced platelets also, peppapani is more convenient to use and can be taken continuously Schonitinib, on the other hand, needs to take the drug for 4 weeks and stop taking it for 2 weeks.